Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report issued on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Up 10.7 %

Shares of GLMD stock opened at $0.40 on Wednesday. The firm has a market cap of $2.02 million, a price-to-earnings ratio of -0.12 and a beta of 0.87. Galmed Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $7.80. The stock has a 50-day moving average price of $0.36 and a 200 day moving average price of $0.38.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.